

**REMARKS**

Claims 1-6 were pending in the application. Claims 1-6 have been cancelled and claims 7-15 have been added. Accordingly, claims 7-15 will be pending upon entry of the instant amendments presented herein.

Support for the amendments to claims 7-15 may be found in the claims as originally filed and throughout the specification. In particular, support for claim 7 can be found in the specification at least at page 7, line 30, to page 8, line 3; support for claim 8 can be found in the specification at least at page 7, lines 6-9; support for claim 9 can be found in the specification at least at page 54, lines 20-22; support for claim 10 can be found in the specification at least at page 53, lines 16-25; support for claim 11 can be found in the specification at least at page 5, lines 12-23; support for claim 12 can be found in the specification at least at page 50, lines 12-15; support for claim 13 can be found in the specification at least at page 50, lines 12-15; support for claim 14 can be found in the specification at least at page 6, lines 4-24; and support for claim 15 can be found in the specification at least at page 6, line 25 to page 7, line 5. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

**ELECTION / RESTRICTION**

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

- I. Claim 1, drawn to a protein, classified in class 530, subclass 350.
- II. Claims 2-6, drawn to DNA and host cell, classified in class 435, subclass 69.1.

Applicants hereby elect, without traverse, to prosecute the invention of **Group I** (claim 1). Applicants reserve the right to pursue the non-elected subject matter of the canceled claim in one or more divisional applications.

Additionally, the Examiner has required that upon election of one of the Groups, Applicants are required to elect a single nucleic acid or protein. Accordingly, Applicants hereby elect, without traverse, the polypeptide designated **HP10493** and its corresponding sequence, SEQ ID NO:3. Applicants reserve the right to pursue the non-elected subject matter of the nucleic acids or proteins in one or more divisional applications.

If a telephone conversation with Applicants' Attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



---

Cynthia L Kanik, Esq.  
Registration No. 37,320  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Dated: June 27, 2001